Key result
Targeting energy metabolic pathways is linked to ~100% higher myocardial ketone oxidation in HFrEF.
Why the study?
Energy metabolic changes contribute to heart failure severity but are complex and dependent on heart failure type, severity, and comorbidities such as obesity and type 2 diabetes.
Design
Review
Authors
Loading...
Hypothesis-generating for metabolic modulators in HFrEF; leaves open clinical benefit pending randomized trials.
null
Pharmacological targeting of energy metabolic pathways has emerged as a novel therapeutic approach to improving cardiac efficiency, decreasing the energy deficit, and improving cardiac function in the failing heart.
Lopaschuk et al. (2021) conducted a null in heart failure. pharmacological targeting of energy metabolic pathways was evaluated on myocardial ketone body oxidation. Pharmacological targeting of energy metabolic pathways is associated with increased myocardial ketone body oxidation by approximately 100% in patients with heart failure with reduced ejection fraction (HFrEF).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: